Navigation Links
Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008
Date:5/14/2009

NANTONG CITY, China, May 14 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that production of its flagship drug, Cisatracurium Besylate, increased by 350% in the first quarter of 2009 compared to production in the first quarter of 2008.

In response to a sharp rise in orders, Sinobiopharma increased the total output of the skeletal muscle relaxant to 214,900 units in the first quarter of 2009, compared to 47,700 units for the same period in 2008.

"We were able to achieve the dramatic rise in production despite the global economic crisis and challenges within the Chinese pharmaceutical industry," said Lequn Huang, Company President and CEO. "We anticipate that demand for our flagship product, and for our newly launched anti-hypertensive, Perindopril, will continue to grow. We also expect that this growth, and planned acquisitions in 2009, will drive a higher level of performance for Company this year."

Sinobiopharma distributes Cisatracurium Besylate in 30 provinces and key major cities throughout China through sales partners and other sales networks.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
2. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
3. China Sky One Medical, Inc. Announces Record First Quarter 2009 Results
4. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
5. Birner Dental Management Services, Inc. Announces Net Income up 31% for the Quarter
6. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
7. Concentric Medical Announces Enrollment Milestone for Merci Registry
8. Natural Alternatives International, Inc. Announces Fiscal 2009 Q3 Results
9. eDiets.com(R) Announces Q1 2009 Results
10. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... of Bruton Memorial Library on June 21 due to a possible lice infestation, as reported ... head lice: the parasite’s ability to live away from a human host, and to infest ... in the event that lice have simply gotten out of control. , As lice are ...
(Date:6/25/2016)... ... ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department of Health ... of their exemplary accomplishments in worksite health promotion. , The Wellness at Work Awards ... at the BWI Marriott in Linthicum Heights. iHire was one of 42 businesses to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and ... that call for a minimum wage raise to $12 an hour by 2020 and then ... will restore the lost value of the minimum wage, assure the wage floor does not ...
(Date:6/24/2016)... ... June 24, 2016 , ... Strategic Capital Partners, ... economy by obtaining investment capital for emerging technology companies. SCP has delivered ... already resulted in more than a million dollars of capital investment for five ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... Ill. , June 23, 2016  In a startling report ... are failing their residents by lacking a comprehensive, proven plan to ... a definitive ranking of how states are tackling the worst ... to only four states – Kentucky , ... Vermont . Of the 28 failing states, three ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate ... in Latin America . ... ... ... ...
Breaking Medicine Technology: